# US 12,005,104 B2 · Cancer vaccines for colorectal cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,005,104 B2
- Document ID: US12005104B2
- Status: Granted
- Kind: B2
- Application number: 17/263,290
- Filed: 2019-07-25
- Published: 2021-07-15
- Granted: 2024-06-11
- Earliest claimed: 2018-07-26
- Assignees: CureVac Netherlands B.V.
- Applicants: CureVac Netherlands B.V.
- Inventors: Ronald Hans Anton Plasterk
- Web page: https://patentgrep.com/patent/US12005104B2

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 39/0011: {Cancer antigens}
- A61K 2039/82: {Colon}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to the field of cancer, in particular colorectal cancer. In particular, it relates to the field of immune system directed approaches for tumor reduction and control. Some aspects of the invention relate to vaccines, vaccinations and other means of stimulating an antigen specific immune response against a tumor in individuals. Such vaccines comprise neoantigens resulting from frameshift mutations that bring out-of-frame sequences of the APC, ARID1A, KMT2D, RNF43, SOX9, TCF7L2, TP53, and ZFP36L2 genes in-frame. Such vaccines are also useful for ‘off the shelf’ use.

## Claims

### Claim 1

A therapeutic vaccine or collection of therapeutic vaccines for treating colorectal cancer comprising:
a peptide, or a collection of tiled peptides, having the amino acid sequence selected from SEQ ID NO:709, an amino acid sequence having 90% identity to SEQ ID NO:709, a fragment comprising at least 10 consecutive amino acids of SEQ ID NO:709, or one or more nucleic acids encoding said peptide or collection of tiled peptides; and
a peptide, or a collection of tiled peptides, having the amino acid sequence selected from SEQ ID NO:710, an amino acid sequence having 90% identity to SEQ ID NO:710, a fragment comprising at least 10 consecutive amino acids of SEQ ID NO:710, or one or more nucleic acids encoding said peptide or collection of tiled peptides; preferably also comprising
a peptide, or a collection of tiled peptides, having the amino acid sequence selected from SEQ ID NO:711, an amino acid sequence having 90% identity to SEQ ID NO:711, a fragment comprising at least 10 consecutive amino acids of SEQ ID NO:711, or one or more nucleic acids encoding said peptide or collection of tiled peptides; and/or
a peptide, or a collection of tiled peptides, having the amino acid sequence selected from SEQ ID NO:712, an amino acid sequence having 90% identity to SEQ ID NO:712, a fragment comprising at least 10 consecutive amino acids of SEQ ID NO:712, or one or more nucleic acids encoding said peptide or collection of tiled peptides.

### Claim 2 (depends on 1)

The therapeutic vaccine or collection of therapeutic vaccines of claim 1, wherein at least two of said peptides are linked.

### Claim 3

The therapeutic vaccine or collection of therapeutic vaccines of 2, wherein said peptides are comprised within the same polypeptide.

### Claim 4 (depends on 1)

The therapeutic vaccine or collection of therapeutic vaccines of claim 1, wherein the nucleic acid molecules encoding said peptides are comprised in one or more vectors.

### Claim 5 (depends on 4)

The therapeutic vaccine or collection of therapeutic vaccines of claim 4, wherein said vector is a viral vector.

### Claim 6 (depends on 1)

The therapeutic vaccine or collection of therapeutic vaccines of claim 1, further comprising a pharmaceutically acceptable excipient, an adjuvant, or a therapeutic agent.

### Claim 7 (depends on 6)

The therapeutic vaccine or collection of therapeutic vaccines of claim 6, wherein the therapeutic agent is a checkpoint inhibitor, a chemotherapeutic agent, or an antibody.

### Claim 8 (depends on 6)

The therapeutic vaccine or collection of therapeutic vaccines of claim 6, further comprising an immune-effective amount of adjuvant.

### Claim 9 (depends on 1)

A method of treating an individual for colorectal cancer, the method comprising administering to the individual in need thereof a therapeutic vaccine selected from the therapeutic vaccine or collection of therapeutic vaccines of claim 1.